Quick Facts

• Therapeutic Domains: Acute Coronary Syndrome (ACS), Recent Myocardial Infarction (MI), Recent Stroke, Established Peripheral Arterial Disease (PAD)
• Primary Benefit: Used to reduce the risk of clot-related events such as heart attack and stroke.

---

Лопирел (Clopidogrel) is a prescription medication utilized in cardiovascular management to assist in reducing the likelihood of certain serious events. It is a treatment option for individuals who have experienced a recent heart attack (myocardial infarction), a recent stroke, or who have established peripheral arterial disease. The medication is also part of the management strategy for people diagnosed with Acute Coronary Syndrome (ACS), including unstable angina and certain types of heart attacks (Non-ST-Elevation MI and ST-Elevation MI).

When prescribed, this agent is intended to help decrease the rate of a second heart attack or stroke. A healthcare professional determines if this medication is appropriate for an individual's specific needs and condition. It may be administered in conjunction with aspirin as part of a dual antiplatelet regimen to help manage the risk of clot formation in specific patient populations. This medication is used strictly under the guidance and monitoring of a licensed physician.

Clopidogrel (Лопирел) is an antiplatelet medicine officially restricted to adult patients as its safety and efficacy have not been established in the pediatric population. Official regulatory labeling defines clear populations who must not use this medicine.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated and must not be used by individuals with the following conditions:

• Active Pathological Bleeding: This includes conditions such as bleeding peptic ulcer or bleeding in the brain (intracranial hemorrhage).
• Hypersensitivity/Allergy: Patients with a known severe allergic reaction (e.g., anaphylaxis) to clopidogrel or any other component of the product.
• Severe Hepatic Impairment: Individuals with significant, documented liver dysfunction.

Restricted or Special Consideration Populations

Use is not recommended or requires special consideration in several other populations. This includes patients with severe renal impairment or moderate hepatic disease, as therapeutic experience is limited and bleeding risk is a concern. Furthermore, use is generally not recommended in patients who have had an acute ischemic stroke within the first seven days due to insufficient data. Special attention is also given to individuals known to be CYP2C19 poor metabolizers, as the drug may not work effectively for them.

The official interaction profile for Лопирел (Clopidogrel) is defined by pharmacokinetic and pharmacodynamic constraints documented in government regulatory labeling.

Pharmacokinetic Interactions and Restrictions

Co-administration with the proton pump inhibitors Omeprazole and Esomeprazole is generally discouraged by regulatory agencies, and in some regions, formally classified as contraindicated. These medicines are metabolic inhibitors of the CYP2C19 enzyme, which is required for the conversion of Clopidogrel to its active metabolite, thereby diminishing its antiplatelet effect. The official label also notes that Clopidogrel is an inhibitor of the BCRP transporter, a mechanism that may lead to increased systemic exposure of co-administered BCRP substrate medicines, such as Rosuvastatin and Atorvastatin.

Pharmacodynamic Interactions and Bleeding Risk

The most significant pharmacodynamic constraint relates to the additive risk of bleeding. Concomitant use with oral anticoagulants (like Warfarin) is not recommended due to a substantially increased intensity of bleeding. Caution is also formally advised when combining Clopidogrel with other antiplatelet agents (e.g., Aspirin) and NSAIDs, as these combinations heighten the documented risk of hemorrhagic events.

Population and Procedural Notes

A population-specific interaction factor is the CYP2C19 poor metabolizer status, which is documented to result in lower levels of the active metabolite and a reduced antiplatelet response. Furthermore, the label stipulates a mandatory cessation period, such as discontinuing the medicine five days prior to elective surgery, if an antiplatelet effect is undesirable during the procedure.

Targeting Platelet Aggregation via Irreversible P2Y12 Blockade

The core mechanism of Лопирел is the selective and permanent inhibition of the P2Y12 receptor on the platelet surface, achieved through the formation of a covalent bond by the drug’s active metabolite. This interaction prevents the platelet from receiving the primary activation signal (adenosine diphosphate, ADP), which results in the suppression of cellular cross-linking and aggregation.

Modulation of Intracellular Signaling and cAMP Levels

By preventing P2Y12 receptor activation, the drug fundamentally alters the internal signal transduction cascade within the platelet. This action maintains high intracellular concentrations of cyclic AMP (, cAMP), which is a key inhibitory messenger that sustains the platelet in an inactive, quiescent state, thereby achieving a reduction in the propensity for thrombus formation.

The Constraint of Metabolic Bioactivation (, CYP2C19 Dependence)

The functional mechanism is constrained by the need for Лопирел to be a prodrug that requires metabolic conversion by the CYP2C19 enzyme in the liver to yield the active compound. This bioactivation step dictates the initial time required for the mechanism to become effective and represents a biological factor that influences the efficiency of the final P2Y12 receptor blockade.

How to Use Лопирел

Лопирел (Clopidogrel) is an oral medication that must be used strictly according to prescribing guidelines. The medicine is supplied as a film-coated tablet and is taken once daily, which may be done with or without food.

---

Official Dosing Regimens

Context	Initial Dose Pattern	Maintenance Dose Pattern
Acute Coronary Syndrome (ACS)	Single oral 300 mg loading dose (up to 600 mg in some guidelines)	75 mg once daily
Recent MI, Recent Stroke, Established PAD	None (start maintenance immediately)	75 mg once daily

The standard maintenance therapy is 75 mg once daily for all approved indications. The use of a single, higher loading dose is specifically intended to achieve a faster therapeutic effect in acute settings like ACS. The loading dose may be omitted for medically managed patients over 75 years of age with ST-Elevation Myocardial Infarction.

---

Administration Protocol

For most acute cardiovascular conditions, Clopidogrel is administered in combination with aspirin, known as Dual Antiplatelet Therapy (DAPT). This combination therapy is prescribed for defined periods, ranging from at least four weeks to up to 12 months for certain heart conditions, or long-term for chronic conditions.

If a daily dose is missed by less than 12 hours of the scheduled time, it should be taken immediately. If the dose is missed by more than 12 hours, the missed dose must be skipped entirely, and the next scheduled dose taken as usual; doses should not be doubled.

Research Evidence / Overview of Studies for Clopidogrel

Evidence for Secondary Prevention of Major Vascular Events

The core research for Clopidogrel involves large-scale, long-term Randomized Controlled Trials (RCTs). These studies explored event patterns in adults who had previously experienced a serious vascular event, such as a heart attack, an ischemic stroke, or who had established Peripheral Arterial Disease (PAD). Studies monitored a composite outcome of major events, which included endpoints such as death from a vascular cause, non-fatal myocardial infarction (MI), and non-fatal ischemic stroke.

Research examined Clopidogrel monotherapy against another antiplatelet agent, Aspirin, over defined time intervals lasting for several years. Findings were used to compare event rates between the two treatment approaches in the study populations. What remains uncertain is the direct comparative evidence between Clopidogrel monotherapy and alternative antiplatelet agents for long-term maintenance in all patient groups.

Evidence for Management of Acute Coronary Syndrome (ACS)

For individuals presenting with an Acute Coronary Syndrome (ACS), Clopidogrel was evaluated in studies for short-term changes when used in combination with Aspirin, a regimen known as Dual Antiplatelet Therapy (DAPT). Studies explored a combination of outcomes reflecting episodic changes, including non-fatal heart attack, stroke, cardiovascular death, and urgent procedures needed to restore blood flow.

The findings describe patterns where event rates measured during the study period were compared between the treatment groups. Most of these trials primarily monitored patient responses over time intervals typically up to one year. Comparative evidence is still developing regarding how Clopidogrel-based DAPT compares directly to DAPT regimens using other agents in all specific ACS contexts, and the most appropriate duration for combination therapy across all patient groups is not fully established.

Research on Drug Activity and Genetic Variability

Research describes how studies monitored drug activity related to the liver enzyme known as CYP2C19. Studies explored that common genetic differences (variants) in this enzyme can influence how the body converts Clopidogrel into its active form, affecting the measured drug activity in the blood. Specifically, findings indicated that in patients identified as “poor metabolizers,” the measured levels of platelet inhibition were lower in some studies. This reduced activity was associated with clinical event patterns reported in some studies.

Key Studies & References Clopidogrel Therapy and CYP2C19 Genotype (FDA/NCBI Medical Genetics Summaries)

Common questions about Лопирел (FAQ)

Q: How quickly should I expect Лопирел to start working?

Studies on the medicine's activity show that its effect on platelets begins within two hours after a single dose is taken. For the medicine to reach its full, steady antiplatelet effect, official product information indicates that it typically requires between 3 to 7 days of continuous daily use.

Q: Can Лопирел affect my liver function?

Severe liver impairment is listed in official documentation as a contraindication, meaning the medicine should not be used in this circumstance. Caution is generally advised for patients who have active liver disease. Official safety information also documents rare occurrences of acute liver failure.

Q: What are the long-term side effects associated with taking Лопирел for many years?

Clinical trials have examined the use of this medicine for periods of one year or more. The most consistently documented long-term risk relates to bleeding (hemorrhage), which is a characteristic of the medicine's intended action. Official information notes that rare but serious events, such as Thrombotic Thrombocytopenic Purpura (TTP), have been reported following use.

Q: Does Лопирел interact with vitamins or herbal supplements?

While regulatory documents specifically caution against certain prescription drug interactions, there is no universal contraindication against all vitamins or supplements. Official labels advise patients to always inform their healthcare provider about every medicine, vitamin, and herbal supplement they use, as some products (like those increasing bleeding risk) require attention. Use is typically discussed with a healthcare provider.

Q: Is it safe to drive while taking Лопирел?

Official documents state that the medicine is unlikely to affect the ability to drive or use machines. However, patients should be aware that uncommon side effects, such as dizziness or vertigo, are reported and could potentially impact the ability to operate machinery safely.

Q: Does taking Лопирел make it harder for wounds to heal?

The medicine works by reducing the ability of blood platelets to form a clot, which is a necessary step in stopping bleeding. Official patient information advises that it may take longer than usual to stop bleeding if a person cuts or injures themselves. This is a direct consequence of the medicine's designed antiplatelet effect.

Q: Can Лопирел be taken for conditions other than heart issues?

Official prescribing information confirms that the medicine is used to reduce the risk of cardiovascular events in patients with certain conditions. These conditions include recent heart attack, recent stroke, and established Peripheral Arterial Disease (PAD), a vascular condition affecting the limbs.

Q: Is Лопирел a blood thinner?

The medicine is formally classified as an antiplatelet agent. This means its specific role is to prevent blood platelets from sticking together to form clots. Although it affects the blood’s ability to clot, its mechanism is distinct from traditional anticoagulants (which are also often called 'blood thinners').

Q: Can I take pain relievers like ibuprofen with Лопирел?

Regulatory documents advise caution when taking this medicine in combination with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes pain relievers like ibuprofen. This combination is documented to substantially increase the risk of gastrointestinal bleeding, and its use should be reviewed by a healthcare provider.

Q: What happens if a dose of Лопирел is missed?

Official administration guidelines indicate that if a dose is missed by more than 12 hours past the scheduled time, the missed dose is skipped, and the next scheduled dose is taken as usual. Doses are not intended to be doubled to make up for a missed one.

Q: Is Лопирел safe for elderly patients?

The medicine is formally indicated for use in adults and the elderly population. Clinical studies and official documentation have shown that the overall safety and side effect profile in elderly patients (including those 75 years and older) is comparable to that observed in younger adults.

Q: Is Лопирел an aspirin replacement?

No, the medicine is not generally considered a replacement for aspirin. In many acute cardiovascular settings, official prescribing protocols indicate that the medicine is used in combination with aspirin (known as Dual Antiplatelet Therapy). The specific purpose and combination regimen are determined within the overall treatment plan.

Q: How does Лопирел compare to other similar drugs (in general)?

Clinical research has examined the medicine primarily in comparison to aspirin for certain outcomes. Official documents indicate that evidence is still developing regarding direct comparisons between this medicine and other alternative antiplatelet agents for long-term maintenance across all patient groups.

Q: Is a generic version of Лопирел equally effective?

In many regions, generic versions of a brand-name drug are required to demonstrate bioequivalence to the original product. Bioequivalence means that the generic formulation delivers the same amount of the active ingredient into the bloodstream over the same period, which is the basis for their use as therapeutic equivalents.

Q: Has there been recent research on new uses for Лопирел?

While the core official indications are for preventing specific vascular events, official sources note that the medicine is sometimes used in specific clinical contexts outside the established label. The medicine is intended for use within its officially established indications.

Q: What are the restrictions on who can use Лопирел?

The use of the medicine is officially restricted to adults 18 years and older as its safety and effectiveness have not been established in children. Furthermore, it is contraindicated (must not be used) in patients with active pathological bleeding, severe liver impairment, or a documented allergy to the drug.

Q: Will I need to be on Лопирел for the rest of my life?

The official duration of treatment varies significantly based on the patient's specific condition and history. While combination therapy with aspirin is often for a defined period, the medicine is commonly used for the long-term prevention of events in chronic vascular conditions. The precise duration of treatment is part of the patient's overall treatment plan.

Q: Is a rash a sign of a serious side effect from Лопирел?

A rash is generally listed as an uncommon side effect. However, patients should be aware that more severe skin reactions, such as widespread rash, hives, or swelling of the face, lips, or throat, have been reported and are signs that immediate medical evaluation may be warranted.

Q: Does Лопирел help with circulation in the legs?

Yes, the medicine is officially indicated to reduce the risk of serious vascular events in patients who have established Peripheral Arterial Disease (PAD). PAD is a condition that involves poor circulation in the blood vessels that supply the limbs, including the legs.

Q: What is the function of the plaque or clots that Лопирел is intended to address?

The medicine is designed to help prevent the formation of pathological blood clots that can occur in blood vessels affected by underlying disease (plaque). It works by inhibiting platelets from sticking together to form the cellular component of these clots, helping to maintain blood flow.

Q: Is Лопирел only for people who have already had an event, or is it preventative?

The medicine is used for secondary prevention. This means its official purpose is to be used in patients who have already experienced a serious vascular event (such as a heart attack or stroke) to reduce the likelihood of the event recurring in the future.

Q: Can I take general antacids or stomach protectors with Лопирел?

Specific stomach acid reducers known as Proton Pump Inhibitors (like omeprazole) are discouraged because they can reduce the medicine's effectiveness. However, official information does not indicate an interaction with general, non-prescription antacids (like calcium carbonate).

Q: What are the non-heart related uses people sometimes ask about for Лопирел?

The primary official uses relate to the prevention of heart attack, stroke, and vascular events due to Peripheral Arterial Disease. However, official sources note the medicine is sometimes used in specific cases to prevent blood clots associated with other conditions, such as atrial fibrillation.

Official Storage and Disposal Requirements for Clopidogrel

Clopidogrel tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The product is required to be kept in its original, tightly closed, light-resistant container to protect it from excessive moisture and light degradation. It is a mandatory requirement that the medicine be stored out of the sight and reach of children to prevent accidental ingestion.

For disposal, unused or expired Clopidogrel must be discarded strictly according to local regulations. Regulatory guidelines in many regions advise against disposal via household wastewater or general trash and instead recommend specialized pharmaceutical return programs.